Source comparison
Thymosin Alpha-1 50s Age Specific Protocol: Dosing & Frequency Comparison
Single 1.6mg injection weekly Once per week 1.6mg 8–12% increase over 12 weeks High. Single injection reduces compliance burden Suboptimal for 50+ due to insufficient IL-6 suppression; does not cross cumulative threshold for inflammaging mitigation Split-dose
This comparison does not assign a generated winner or score.
- Single 1.6mg injection weekly
- Once per week
- 1.6mg
- 8–12% increase over 12 weeks
- High. Single injection reduces compliance burden
- Suboptimal for 50+ due to insufficient IL-6 suppression; does not cross cumulative threshold for inflammaging mitigation
- Split-dose 1.6mg twice weekly
- Every 3.5 days (Mon/Thurs pattern)
- 3.2mg
- 18–24% increase over 12 weeks
- Moderate. Requires discipline but manageable
- Evidence-supported standard for 50+ population; achieves IL-6 suppression and maintains stable plasma levels
- Daily microdosing 0.5mg
- 7 days per week
- 3.5mg
- 12–16% increase over 12 weeks
- Low. Daily injections create fatigue and site rotation challenges
- Higher cumulative dose but lower per-injection receptor saturation; compliance failure common after 4–6 weeks
- Front-loaded 3.2mg twice weekly (first 4 weeks) → 1.6mg maintenance
- Twice weekly, dose reduction at week 5
- 6.4mg (weeks 1–4), 3.2mg (weeks 5+)
- 22–28% increase over 12 weeks
- Moderate. Requires protocol transition discipline
- Advanced strategy for severely immunocompromised; not necessary for healthy 50+ individuals